Trial Profile
A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Olopatadine (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Alcon
- 28 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov record.
- 23 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov record